Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes
出版年份 2022 全文链接
标题
Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes
作者
关键词
chronic kidney disease, finerenone, mineralocorticoid receptor, mineralocorticoid receptor antagonist, type 2 diabetes
出版物
Kidney International Supplements
Volume 12, Issue 1, Pages 27-35
出版商
Elsevier BV
发表日期
2022-03-18
DOI
10.1016/j.kisu.2021.11.005
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis
- (2022) James M. Luther et al. Kidney International Supplements
- Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease
- (2022) Toshifumi Nakamura et al. Kidney International Supplements
- The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets
- (2022) Morley D. Hollenberg et al. Kidney International Supplements
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021
- (2021) Peter Rossing et al. AMERICAN JOURNAL OF MEDICINE
- 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
- (2021) Peter Rossing et al. Kidney International Reports
- Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
- (2020) Nete Tofte et al. Lancet Diabetes & Endocrinology
- Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
- (2020) Matteo Serenelli et al. JACC-Heart Failure
- TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment
- (2020) Ian H. de Boer et al. KIDNEY INTERNATIONAL
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
- (2020) Rajiv Agarwal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial
- (2020) Peter Rossing et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
- (2019) Josef Coresh et al. Lancet Diabetes & Endocrinology
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Mitigating risk of aldosterone in diabetic kidney disease
- (2019) Marie Frimodt-Møller et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy
- (2018) Yingying Chen et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
- (2018) N. Tofte et al. DIABETIC MEDICINE
- Cardiorenal Syndrome Revisited
- (2018) Faiez Zannad et al. CIRCULATION
- Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013
- (2018) Digsu N. Koye et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- (2018) David M. Charytan et al. KIDNEY INTERNATIONAL
- Diabetes with early kidney involvement may shorten life expectancy by 16 years
- (2017) Chi Pang Wen et al. KIDNEY INTERNATIONAL
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis
- (2015) Jing Hou et al. CLINICAL THERAPEUTICS
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study
- (2015) ChongTing Lin et al. Journal of Clinical Hypertension
- Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis
- (2015) Bin Wang et al. Lancet Diabetes & Endocrinology
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determinants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt Nephropathy
- (2013) O. Moranne et al. Clinical Journal of the American Society of Nephrology
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus
- (2013) Christina S. Oxlund et al. JOURNAL OF HYPERTENSION
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study
- (2012) S. E. Nielsen et al. DIABETIC MEDICINE
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a Retinal Aldosterone System and the Protective Effects of Mineralocorticoid Receptor Antagonism on Retinal Vascular Pathology
- (2008) Jennifer L. Wilkinson-Berka et al. CIRCULATION RESEARCH
- Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
- (2008) George Bakris et al. KIDNEY INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now